Update shared on04 Aug 2025
Fair value Decreased 19%Baxter International’s consensus analyst price target has been significantly reduced, primarily driven by downward revisions in both revenue growth forecasts (from 5.2% to 3.7% per annum) and net profit margin (from 7.71% to 7.02%), resulting in a new fair value estimate of $29.89.
What's in the News
- Baxter provided Q3 and full-year 2025 sales guidance, projecting 6–7% reported sales growth from continuing operations and 3–4% operational growth.
- Vizient expanded its Reserve Program to include IV fluids via a strategic partnership with Baxter, enhancing supply chain resilience for critical products in the US healthcare system.
- Andrew Hider was appointed as Baxter's new CEO, bringing extensive global leadership experience in life sciences and automation, with a strong track record at ATS Corporation.
- Baxter will distribute Pieces Technologies’ Inpatient Platform, offering AI-driven documentation and care coordination tools to US hospitals and health systems.
- Baxter introduced Hemopatch Sealing Hemostat with room-temperature storage, an extended 3-year shelf life, and enhanced tissue-sealing and hemostatic properties.
Valuation Changes
Summary of Valuation Changes for Baxter International
- The Consensus Analyst Price Target has significantly fallen from $37.09 to $29.89.
- The Consensus Revenue Growth forecasts for Baxter International has significantly fallen from 5.2% per annum to 3.7% per annum.
- The Net Profit Margin for Baxter International has fallen from 7.71% to 7.02%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.